Urothelial Cancer

Oncology·MeSH: Carcinoma, Transitional Cell

20 drugs in development·12 companies·19 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
jelmyto	UroGen Pharma Ltd. (URGN)

Phase 3(7)

Drug	Company
Cabozantinib S-malate	Merus N.V. (MRUS)
epacadostat	Incyte Corp. (INCY)
MEDI4736	ASTRAZENECA PLC (AZN)
pemigatinib	Incyte Corp. (INCY)
sacituzumab govitecan	Phoenix Life Sciences International Limited. (PLSI)
ugn-501	UroGen Pharma Ltd. (URGN)
vinflunine	Phoenix Life Sciences International Limited. (PLSI)

Phase 2(7)

Drug	Company
BT8009	BICYCLE THERAPEUTICS PLC (BCYC)
Iza-bren	Merus N.V. (MRUS)
Pegfilgrastim	ADMA BIOLOGICS, INC. (ADMA)
Vinblastine Sulfate	ENANTA PHARMACEUTICALS INC (ENTA)
Vinblastine Sulfate	Structure Therapeutics Inc. (GPCR)
zelenectide pevedotin	BICYCLE THERAPEUTICS PLC (BCYC)
zelenectide pevedotin (formerly BT8009)	BICYCLE THERAPEUTICS PLC (BCYC)

Phase 1(2)

Drug	Company
enfortumab vedotin	Generate Biomedicines Inc. (GENB)
gb-4362	Generate Biomedicines Inc. (GENB)

Phase 1/Phase 2(2)

Drug	Company
Enfortumab Vedotin	PFIZER INC (PFE)
PF-08634404	PFIZER INC (PFE)

Phase 2/Phase 3(1)

Drug	Company
iza-bren	BRISTOL MYERS SQUIBB CO (BMY)

BioSniper tracks 20 drugs in development for Urothelial Cancer across 12 companies.

There are 19 clinical trials targeting Urothelial Cancer tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.